Summary: A new study finds that administering minocycline to newborn rats after a head injury worsened cognitive outcomes.
Source: Drexel University.
Traumatic brain injury (TBI) is a leading cause of disability and death among infants and young children in the United States. According to public health statistics, more than half a million children are affected each year, and those under age four who suffer brain trauma often face lifelong challenges with memory, attention, and other executive functions.
Currently, no approved drug therapies exist specifically to treat these pediatric brain injuries. In adult animal models, however, certain antibiotics that dampen the brain’s inflammatory response have shown promise in reducing long-term damage after head trauma.
New research from Drexel University College of Medicine indicates that the same approach may be harmful in the immature brain. The study, published in the journal Experimental Neurology, reports that the FDA-approved antibiotic minocycline, when given to newborn rats immediately after closed head injury, exacerbated cognitive deficits rather than improving outcomes.
“The developing brain is not the same as the fully mature brain,” said Ramesh Raghupathi, PhD, professor of neurobiology and anatomy at Drexel. “These results suggest that acute interventions focused on blocking the inflammatory cascade may not be a viable treatment strategy for traumatic brain injury in infants and very young children.”
Minocycline reduces activation of microglia, the brain and spinal cord’s resident immune cells that respond to pathogens and injury. In adult models of brain injury, limiting microglial activation has been associated with reduced neuronal degeneration and improved behavioral outcomes, which makes repurposing an FDA-approved drug such as minocycline an attractive strategy.
In the pediatric rat model used by the Drexel team, the immediate microglial response to injury resembled what is typically observed in adult brains: substantial cell death, tissue damage, and inflammation. Researchers hypothesized that suppressing microglial activation with minocycline would protect the developing brain and improve recovery.
However, short-term treatment—one dose per day for three days—did not improve measures of brain activity or function. When the treatment was extended to nine days, the treated animals exhibited significantly worse memory and other behavioral deficits compared with untreated injured animals.
Raghupathi and colleagues propose that microglia perform vital developmental functions in the neonatal brain, including clearing dead cells and cellular debris to enable healthy neural circuitry to form. By reducing microglial activity immediately after injury, minocycline may have interfered with the brain’s natural repair and maturation processes, hindering recovery.
“You can think of microglia in a developing brain like a garden rake that clears debris so the grass can grow evenly,” Raghupathi explained. “Removing that cleanup process early on can prevent the developing brain from rewiring itself correctly.”
Although acute suppression of inflammation did not benefit the neonatal animals in this study, the researchers note that timing of intervention may be critical. They plan follow-up experiments that delay treatment for two to three weeks after injury, allowing more time for early developmental processes to occur before attempting to modify longer-term inflammatory responses.
“We believe that persistent, long-term inflammation may be a more appropriate therapeutic target than immediate, acute inflammation in the immature brain,” Raghupathi said.
This study was conducted by Lauren Hanlon, a PhD candidate at Drexel University College of Medicine, with coauthors including Jimmy Huh, MD, an associate professor at the Children’s Hospital of Philadelphia.
Funding: Supported by the National Institutes of Health / National Institute of Child Health and Human Development.
Source: Lauren Ingeno, Drexel University.
Image source: Image adapted from Drexel University press materials.
Original research: Abstract published in Experimental Neurology for the study titled “Differential effects of minocycline on microglial activation and neurodegeneration following closed head injury in the neonate rat.”
The study examined the role of microglia after closed head injury in 11-day-old rats and evaluated two minocycline dosing regimens. In the first experiment, three days of minocycline treatment reduced microglial reactivity in cortex and hippocampus immediately after dosing but coincided with increased markers of degenerating cells, suggesting impaired clearance of damaged cells; these effects were not sustained at one week post-injury. Minocycline did not reduce axonal injury or degeneration in white matter or thalamus, and spatial learning deficits induced by injury were unchanged.
In a second experiment, nine days of minocycline led to increased microglial reactivity and neurodegeneration in multiple brain regions immediately after treatment, with persistent effects in cortex and hippocampus observed up to 15 days post-injury. While minocycline did not lessen injury-induced spatial learning deficits, memory impairments were significantly worse in treated animals. Sex had minimal influence on injury outcomes or treatment response. Overall, these results demonstrate that minocycline produces differential and, in some cases, detrimental effects in the immature brain following impact injury, indicating it may not be an effective therapeutic strategy for pediatric TBI.